Coherus BioSciences - CHRS Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHRS shares.
View CHRS analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12 month target prices for Coherus BioSciences' stock. Their CHRS share price forecasts range from $7.00 to $30.00. On average, they anticipate the company's share price to reach $18.40 in the next year. This suggests a possible upside of 33.7% from the stock's current price.
View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts.

Coherus BioSciences' stock was trading at $15.96 at the beginning of the year. Since then, CHRS shares have decreased by 13.8% and is now trading at $13.76.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our CHRS earnings forecast.

Coherus BioSciences, Inc. (NASDAQ:CHRS) released its earnings results on Thursday, August, 4th. The biotechnology company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.17. Coherus BioSciences had a negative trailing twelve-month return on equity of 422.10% and a negative net margin of 83.47%. During the same period last year, the firm earned ($0.40) earnings per share.

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Coherus BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (1.39%), Northern Trust Corp (0.96%), Scout Investments Inc. (0.89%), Deutsche Bank AG (0.88%), Platinum Investment Management Ltd. (0.77%) and Principal Financial Group Inc. (0.61%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends.

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHRS stock can currently be purchased for approximately $13.76.

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $1.07 billion and generates $326.55 million in revenue each year. The biotechnology company earns $-287,100,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis.

The company employs 332 workers across the globe.

Coherus BioSciences was founded in 2010.

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.